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THESIS  12_21_12   
Ye, Qing. M. S., Department of biochemistry and Molecular Biology, Wright State 
University, 2012. “Lipase-Kinase Associations Involving PLD2, Jak3 And Fes That Underlie 
Cancer Cell Proliferation And Invasion”.   Director: Julian G. Cambronero, Ph.D. 
 
ABSTRACT 
 Phospholipase D (PLD) is an enzyme that breaks down phospholipids in the cell 
membrane. It has been suggested that PLD may play a role during cell proliferation and cell 
invasion of cancer cells. The objective of this thesis was to define new molecular signaling 
pathways in which PLD2 might be involved in terms of cell proliferation (first part) and cell 
invasion (second part). To this, I compared molecular and biochemical aspects between 
untransformed cell lines with highly invasive, transformed breast cancer cells. 
In the first part, I investigated the interaction of two tyrosine kinases with PLD2 and the 
effect of such interaction on cell proliferation in the highly invasive MDA-MB-231 breast cancer 
cells. I found that the activities from the two kinases and from PLD2 are all augmented in the 
cancer cells while the protein levels are only relatively high in these cells. JAK3 upregulates 
PLD2 activity in MDA-MB-231 cells while inhibits PLD2 in the untransformed breast epithelial 
MCF10A cells. Fes interacts with PLD2 at distinct binding sites in MDA-MB-231 cells 
compared to MCF10A cells. I also found that phosphatidic acid (PA), the product of PLD 
enzymatic activity, enhances Fes activity in MDAMB-231 cells but not in MCF10A cells. 
Further, I demonstrate that the two tyrosine kinases JAK3 and Fes also interact with each other, 
with Fes having an inhibitory effect on JAK3 in MCF10A cells but not in cancer cells. The 
balanced PLD2 activity by JAK3, Fes and PLD2 interactions in the MCF10A cells keeps PLD2 
at basal level that lead to normal cell growth. In contrast, in MDA-MB-231 cancer cells, the 
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effect of positive feedback among the three proteins and then enhancing effect of PA contribute 
to augmented proliferation. 
            In the second part of this thesis, I investigated the role of JAK3 on PLD2 activities during 
cell invasion in MDA-MB-231 cells using a small-molecule tyrosine kinase inhibitor, the 
flavonoid apigenin (4’,5,7-trihydroxyflavone), as well as RNA silencing. I found that that both 
JAK3 and the tyrosine kinase, Epidermal Growth Factor Receptor (EGFR) are sensitive to the 
inhibitors and directly regulate PLD2 and induce the highly invasive phenotype of MDA-MB-
231 cells. Further, serum-deprived cells in culture show an upregulated EGFR/JAK3/PLD2-PA 
system and are especially sensitive to a combination of JAK3 and PLD2 enzymatic activity 
inhibitors (i.e. 30 nM apigenin and 300 nM 5-Fluoro-2-Indolyl des-Chlorohalopemide [FIPI], 
respectively). Accordingly, cell invasion is enhanced by two kinases (EGFR and JAK3) and a 
phospholipase (PLD2) on multiple levels that provides regulatory flexibility and contribute to 
maximum aggressiveness in cell invasion in MDA-MB-231 breast cancer cells. This is especially 
important during serum starvation that coincides with migration of these cells to new locations. 
            In this thesis, I have demonstrated the existence of new signaling pathways: JAK3-Fes-
PLD2 that plays a central role in cancer cell proliferation and EGFR-JAK3-PLD2 that facilitate 
cell invasion. These new pathways might be important to be used as therapeutic targets aimed at 
controlling the high proliferative and invasive phenotype of breast cancer cells.  
 
 
 
 
 
3 
 
TABLE OF CONTENTS 
 
                                                              
Page                                                                                                
I. INTRODUCTION……………………………………………………………...…………1 
 
II. LITERATURE REVIEW………………………….………………………………...……2 
HISTORY AND BACKGROUND OF PLD………………………….………………….………..2 
PLD’S ENZYMATIC ACTIVITY…………………………………………………………….…..2 
CHARACTERISTICS OF PLD………………………..……………………………………….…4 
FUNCTONS OF PLD……………………………….…………………………………………..…6 
REGULATION OF PLD2………………………………………………………………………....9 
FELINE SARCOMA ONCOGENE (FES)…………………………………………………...…...9 
JANUS KINASE 3 (JAK3)…….…………………………………………………………..…….11 
             TRANSFORMED AND UNTRANSFORMED CELL LINES MODELS……………………....13 
INHIBITORS………………………………………………………………………………….….15 
THE PA SENSOR………………………………………………………………………………..16 
 
III. HYPOTHESIS AND SPECIFIC AIMS……………………………...…………………19 
 
IV. METERIALS AND METHODS…………….…….…………………………………….21 
 
V. RESULTS……………………………………………………………………………30 
 
VI. CONCLUSIONS AND DISCUSSION….………………………………………………70 
 
VII. SIGNIFICANCE OF THIS STUDY……………………………….……………….78  
 
VIII. REFERENCES…………………………………………………………………………..79 
 
 
 
4 
 
LIST OF FIGURES 
FIGURES                                                                                                                                   Page                                                                                                
1. PLD chemical reaction…...………………………………………………………………..3 
2. PLD main characteristics……….…………………………………………………………5 
3. Site-directed mutations in PLD2…………………………………………………………7 
4. Domain structure of Fes…………………………………………………………….…10 
5. Domain structure of JAK3 ………………………………………………………………12 
6. Schematic structure of apigenin and FIPI………………………………………..............17 
7. Schematic representation of Matrigel assay for cell invasion analysis…………………..25 
8. Endogenous JAK3, FES, and PLD2 activity levels in untransformed and transformed 
cells....................................................................................................................................31 
9. Analysis of wild type and mutant JAK3, Fes and PLD2 proteins……………….………33 
10. Effect of JAK3 on PLD2 activity in non-transformed versus transformed cells…..….....36  
11. Effect of Fes on PLD2 activity in non-transformed versus transformed cells …..……....39 
12. Interplay between phosphatidic acid and Fes and JAK3 kinases………………….…44 
13. Interaction between JAK3 and Fes kinases……………………………….......................47 
14. The effect of PLD2, Fes or JAK3 overexpression or silencing on cell proliferation in non-
transformed versus transformed cells ………………………………………................50 
15. Model for the new PLD2-Fes-Jak3 pathway……………………………………..52    
16. PLD2 is inhibited by JAK3 in exponentially growing MDA-MB-231 cells….................55 
17. JAK3 stimulates cell invasion after cell starvation…………………………...……58 
18. The JAK3 tyrosine kinase inhibitor apigenin inhibits cell invasion……………...……60 
19. Apigenin inhibits both the rate and the extent of cell invasion…………………………..63 
20. JAK3 effect on PLD2 is reversed by apigenin and by silencing JAK3……………64 
21. An upregulation of Cell invasion by PLD2 and JAK3 overexpression is abrogated by 
apigenin and FIPI treatment…………………………………………………………….66 
22. The JAK3-PLD2 system underlies the highly invasive phenotype of cancer cells…...…69 
 
 
5 
 
ACKNOWLEDGEMENTS 
I would like to thank Dr. Julian Gomez-Cambronero for the opportunity to do research in his lab. 
He is always there to keep me motivated and guided me throughout my project. I thank Karen 
Henkels, who is always ready to answer my questions patiently and gave me her full support 
whenever needed. I would also like to thank my lab colleagues, including Madhu Mahankali, 
Samuel Kantonen and Ramya Ganesan, for their help in the past two and a half years.  I also 
thank my committee members Dr. Steven Berberich and Dr. Gerald Alter and, my program 
director Dr. Madhavi Kadakia for their guidance throughout my stay here. Finally I would like to 
thank the BMB department of which I am honored to have been part of and having received 
support from.  
 
 
 
 
 
 
 
 
 
 
6 
 
I. INTRODUCTION 
Proliferation and Invasion of Breast Cancer 
 Breast cancer is one of the most common forms of cancer in the world, and it accounts 
for a quarter of all cancers in women. Breast cancer is particularly dangerous s due to its ability 
to metastasize to other parts of the body, such as the lungs. Metastasis is the primary cause of 
mortality in patients afflicted with breast cancer (130). One of the means to abrogate the rampant 
metastasis is through disruption of cell proliferation, which is defined as the rate at which the 
cells multiply. In this study, I selected MDA-MB-231 cells as an ideal model due to their high 
rate of proliferation and PLD2’s impact on MDA-MB-231 cells (148). MDA-MB-231 cells 
possess the WNT7B oncogene, which leads to a disruptive expression of several genes (86). This 
knowledge coupled with PLD2’s uncontrolled activity suggested that deregulation possibly 
stemmed from proteins which affect PLD2 activity. By examining some of the root causes of 
uncontrolled PLD2 activity in these cells, it is hoped that I could extrapolate how and why PLD2 
is activated constitutively in other cancers and develop therapies, which could target these 
pathways in cessation of tumor growth or metastasis. 
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II. LITERATURE REVIEW 
History and Background of PLD  
PLD was initially described in plants, specifically carrots. Hanahan and Cahikoff first 
characterized its enzymatic activity in homogenates from vegetables (44, 45). PLD was later 
characterized in viral (124), prokaryotic (93) and eukaryotic (106, 129) organisms, and its 
activity was found to be a consequence of applied cellular stimuli. Since the early 1980s when 
mammalian PLD activities were first described (46, 117, 131), numerous studies on cellular 
models as well as genetic models have been conducted to characterize the physiological and 
pathophysiological functions of PLD. Many findings have found an association of PLD with 
cancer (5, 52, 65, 135), neuronal pathophysiology (9, 132, 144), cardiovascular topics (137, 138, 
140), spermatogenesis (69) and infectious diseases (55, 56). Therefore, further understanding and 
characterization of PLD is essential for a complete understanding the cause of these conditions. 
PLD’s Enzymatic Activity 
PLD employs water as a nucleophile to allow the breaking of the phosphodiester bond of 
the polar head of phosphatidylcholine (PC), which releases choline and membrane lipid 
phosphatidic acid (PA) (Figure 1). Apart from PC breakdown, PLD in the presence of alcohols 
like ethanol or butanol can catalyze the transphosphatidylation reaction resulting in the formation 
of phosphatidylalcohols (33, 113). The advantage of this reaction is that in the laboratory, 
tritium-labeled butanol would yield phosphatidylbutanol, if PLD is present in the samples, which 
is easily separated via thin layer chromatography and counted in a scintillation counter. This is 
the primary method in which I quantify PLD activity. 
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Figure 1. PLD chemical reaction. Upper half, PLD catalyzes the hydrolysis of PC to generate 
choline and PA. Lower half, PLD regulators and effectors. 
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Characteristics of PLD  
The PLD superfamily is composed of a diverse group of proteins that include enzymes 
involved in phospholipid metabolism, a bacterial toxin, poxvirus envelop proteins and bacterial 
nucleases (Fig. 2). There are two classic mammalian isoforms of PLD, PLD1 (42) and PLD2 
(26), which share 52% identity (Figure 2A). PLD1 is a 1072 amino acid, 120 kDa protein, while 
PLD2 is a 933 amino acid, 103 kDa protein. Both isoforms require phosphatidylinositol 4,5-
bisphosphate (PIP2) as a co-factor for activity and release structurally identical PA species in 
mammalian cells.   
PLD1 and PLD2 differ by their tissue and subcellular distribution. Human PLD1 is less 
abundant in comparison of high and variable levels of PLD2 mRNA in tissues (145). PLD2 is 
expressed more abundantly in blood leukocytes but it is expressed at low levels in liver and 
skeletal muscles (114). Both isoforms are found elevated in cancers with high tyrosine kinase 
expression, such as breast cancer tissues (135). Based on studies with PLD inhibitors it was 
found that cell proliferation in MDA-MB-231 cells rely more on PLD2 than on PLD1 (112). 
PLD1 is localized to secretory granules and lysosomes and is translocated to the plasma 
membrane upon cellular stimulation (78). In contrast, PLD2 localizes in sarcolemmal 
membranes, plasma membranes or the rims of the Golgi apparatus (109, 110), and it is 
constitutively expressed. 
PLD1 contains a negatively regulatory loop region (66) that modifies PLD1’s activity 
upon caspase cleavage (105). The smaller PLD2 protein lacks the loop structure, which results in 
differential response to certain regulatory molecules such as GTPases.  On the other hand, PLD1 
and PLD2 share two highly conserved catalytic HKD sequences (HXKX4DX6), which are  
10 
 
 
 
Figure 2. PLD main characteristics. (A) The PLD superfamily include two classic PLD, PLD1 
and PLD2,  and non-classic PLDs. (B) Both PLD1 and PLD2 share two catalytic HKD domains, 
PH and PX domains. PLD2 does not bear a loop region that exists in PLD1. The “loop” is a   
non-conserved 120 amino acid stretch. Human PLD is expressed in blood leukocytes and in 
cancer cells. PLD1 has a constitutive low basal level of activities while PLD2 activity level is 
high. 
!"
A"
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critical for their lipase activity (Figure 2B.). Further, an association of N- and C-terminal region 
of PLD1 is required for catalytic activity. Other conserved features in the PLD family include a 
PIP2 binding site, pleckstrin homology (PH) and phox homology (PX) domains. PIP2 binding is 
required for the enzyme activity of PLD. The N-terminus of the PH domain contains two SH2-
binding motifs and is critical for a PLD-aldolase interaction. The PX domain is also located at 
the N-terminus of PLD and is involved in intracellular protein localization and, binds to proteins 
or lipids. Both the PH and PX domains are important for the regulation of the lipase activity. 
Residues Y169 and Y179 (31) within the PX domain have been shown by our lab to be 
important for docking of SH2-containing proteins and Y415 has been shown to facilitate JAK3 
binding (47) (Figure 3), which will be subjected to mutagenesis to generate PLD2 mutants in this 
thesis. 
Functions of PLD 
Our laboratory has sought to study the role of PLD2 in cancer cell invasion and 
metastasis. A participation of PLD in cell migration was initially documented in leukocytes (41, 
82). Subsequently, it has been explained in other cell types that PLD2 induces cell migration and 
invasion  in human cancer cells (148), phagocytes (16, 41, 82, 92), fibroblasts (72, 101) and 
epithelial cells (11, 87).  S6K (72), Rac2 (17), tyrosine kinase Fer (53, 97) and phosphocofilin 
(43) are also involved in PLD2 mediated invasion.   
PLD has also been documented to generate apoptotic signals in the signal transduction 
pathway (61, 79, 141) through increased expression of Bcl-2 and Bcl-xL (99). Inhibition of PLD 
signal transduction by famesol enhanced apoptosis (128). PLD also postpones or inhibits  
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apoptosis by attenuating the expression of the tumor suppressors early growth response-1 and 
phosphatase and the tensin homologue is deleted on chromosome 10 (67).  In terms of cell 
proliferation and mitogenesis, PA, product of PLD’s cellular enzymatic activity, is associated 
with proliferation in osteoblastic (15) and pheochromocytoma PC12 cells (77). Elevated PLD 
levels prevent cell cycle arrest induced by high intensity Raf signaling (58).  Inhibition of PLD 
expression by triptolide reduces proliferation in MDA-MB-231 breast cancer cells (60). It has 
been suggested that PLD2 is able to induce proliferation through its phosphorylation at residue 
Y179 (29, 81).  
A number of other cellular events are also associated with PLD activity. Some early 
studies have established the role of PLD in membrane traffic (23) which is important for the 
oxidative burst (NADPH oxidase or NOX2) (88) and transport proteins (34). This role of PLD is 
primarily mediated by actin remodeling and the cytoskeleton structure (26, 28), via which PLD 
also regulates adhesion and ruffling.  PLD has also been implicated in cell spreading (18), cell 
membrane ruffling (36) and leukocyte adhesion (91). In T lymphoid Jurkat cells, PLD regulates 
transcription through transcription factor AP-1 and STAT (70). Other roles for PLD include   
mitochondrial fusion (22) and during development (75). 
PLD also exerts its influence over cellular signaling primarily through generation of the 
phospholipid PA. PA is a typically located at the plasma membrane as an important part of the 
phospholipid bilayer (38). PA, as a secondary messenger, is implicated in a wide variety of 
Figure 3. Domain 
architecture of 
PLD2. PLD2 is 
composed of a 
pleckstrin 
homology (PH) 
domain, a phox 
homology (PX) 
domain, and two 
conserved HKD 
domains. Residues 
Y169 and Y179 are 
important in 
docking of SH2-
bearing proteins. 
Residue Y415 is 
essential for 
interaction with 
JAK3 kinase. 
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signaling pathways due to its ability to influence the membrane localization of proteins (73, 147) 
and activate a number of cell signaling enzymes (32, 98, 139). 
 
Regulation of PLD2 
The role of PLD2 in signal transduction has been under investigation by many research 
groups. Two pathways have been established that regulate PLD enzymatic activity. One pathway 
depends on small GTPase proteins for signal transduction, since Arf, Rho and related proteins 
can regulate PLD activity (6, 12, 24, 102).  The other pathways are via tyrosine kinases including 
growth factors/mitogens like EGF, PDGF, insulin and serum for PLD activation (2, 20, 50, 84, 
119). PLD1 has low basal activity that is regulated by phosphoinositides, protein kinase C (PKC), 
small GTPases, like ARF, RhoA, Rac1 and Cdc42, as well as by protein phosphorylation. With 
the regulation of PLD1 well documented, investigation of the regulation of PLD2 is still an 
ongoing work by many researchers. It is known that PLD2 is subjected to comprehensive 
regulation for its activation. Upon activation, PLD can modulate downstream molecules during 
cell signaling through molecules such as mTOR (30), S6K (10) and Ras (7). Higher PLD2 
activity has been found in a number of tumor cells and, therefore, this study focuses on PLD2 
regulation by two tyrosine kinases, Fes and JAK3, in MDA-MB-231 human breast cancer cells.  
Feline Sarcoma Oncogene (Fes)  
 Fes is a 93-kDa non-receptor protein tyrosine kinase encoded by the FES gene (76). It is 
involved in phosphorylation of several substrates which are typically found in macrophage 
function, including cytoskeletal rearrangement (59). Fes additionally phosphorylates substrates 
that lead directly to gene transcription (57). Fes possesses an SH2 domain and an F-BAR domain 
14 
 
(Figure 4), which allow for interaction with a variety of proteins (76, 107). The F-BAR domain 
allows interaction at the cell membrane and interaction with lipids, while the SH2 domain allows  
                                                
 
 
 
 
interaction with a variety of consensus sequences containing phosphorylated tyrosine residues 
(35), (120). The SH2-mediated interaction with substrates is essential for effective Fes signaling 
(35, 120). Mutations of E469 and E472 or R483 in the SH2 domain have been shown to 
eliminate the binding ability of Fes (30, 35). The F-BAR domain cooperates with a number of 
adaptor proteins during Fes’ activity and actin regulation (62). The C-terminal tyrosine kinase 
domain confers its kinase activity of Fes which is abrogated by disruption at residue K590 (89), 
(13). These behaviors make Fes a prime candidate in terms of generation of cancerous 
phenotypes. Fes also demonstrates a unique property in that it is expressed differentially in 
cancer cells. Differentially expressed isoforms of Fes have been shown to cause leukemia via 
unregulated differentiation in certain cancers of the immune system (14).  
Janus Kinase 3 (JAK3) 
Figure 4. Domain 
architecture of Fes. Fes 
has a Tyr kinase domain 
and, a Src homology 2 
(SH2) domain that binds 
to ligands and enhances 
kinase activity. The F-
BAR and FX domains are 
involved in phospholipid 
binding, membrane 
localization and kinase 
activity.  The sites of 
mutagenesis are indicated 
including E469 and E472 
important for ligand 
binding and K590 
essential for kinase 
activity. 
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JAK3 (Figure 5) is a kinase primarily involved in phagocytes and other cells of the innate 
immune system (125). While it is present in every cell at a basal level, it is typically expressed in 
an isoform that prevents kinase activity from becoming too high (74, 104). JAK3 is ~ 121 kDa 
and is composed of seven Janus Homology (JH) domains with an SH2-like motif in the JH4 
domain, which has been shown to be integral in interacting with cytoskeletal proteins (90). 
Additionally, JAK3 has a catalytic kinase domain located in the JH1 domain at K855 (3). The N-
terminal JH6 and JH7 domains regulate cytokine receptors and catalytic activity. Residues R402 
and R403 in the JH4 SH2-like domain are important for ligand binding of JAK3 (3).  
 
                                          
 
Transformed and untransformed cell line models 
MDA-MB-231 cells. A number of cell lines are used in this thesis with the MDA-MB-231 
cell line used as the primary model for transformed human cancer cells. The MDA-MB-231 
breast cancer cell line was isolated from a female patient in 1973 (64, 130). These cells show 
epithelial-like morphology and appear phenotypically spindle shaped (27).  This cell line is 
highly proliferative and metastatic (103). It functions as a valuable model for regulation of gene 
expression and cell proliferation in breast cancer and experimental metastasis. In addition, MDA-
MB-231 cells, which have high levels of mutant p53, have high levels of PLD activity, which 
provides a survival signal in these cells when deprived of serum growth factors (51). 
Figure 5. Domain 
architecture of JAK3. 
JAK3 is composed of 7 
Janus homology domains 
with a C-terminal tyrosine 
kinase domain ( JH1) and 
Src homology 2 (SH2) –
like domain (JH4). The N-
terminus FERM domain 
(JA6 and JH7) regulates 
cytokine receptors binding 
and catalytic activity. 
Residues R402 and R403 
are important for ligand 
binding and K855 is 
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MCF10A cells. I chose the untransformed MCF10A cell line as a negative control for my  
study. The MCF10A cell line is derived from the MCF10 human breast epithelial cell line 
isolated from human fibrocystic mammary tissue (121). Subsequent culturing of MCF10 gave 
rise to MCF10A which is characterized as untransformed breast epithelium cells (71, 89, 121). 
MCF10A cells are positive for epithelial sialomucins, cytokeratins and milk fat globule antigen 
and exhibit three-dimensional growth in collagen and form domes in confluent cultures (40). 
This cell line is responsive to insulin, cholera enterotoxin, glucocorticoids, and epidermal growth 
factor (EGF) (71). Using electron microscopy, these cells display characteristics of luminal 
ductal cells but not of myoepithelial cells. Cell morphology is strongly affected by the calcium 
content of the medium. MCF10A cells also express breast specific antigens detected by positive 
reaction with MFA-breast and MC-5 monoclonal antibodies (40). This cell line expresses wild 
type  p53 tumor suppressor. 
COS-7 cells. COS-7 cells are derived from the CV1 cell line which was isolated in the 
1960s from an African green monkey kidney (142). The COS-7 cell line was developed through 
CV1 transformation with a Simian Vacuolating Virus 40 (SV40), a virus that codes for the wild 
type virus T-antigen. COS-7 cells thus express the SV40 T-antigen and retain its susceptibility to 
SV40, which grows lytically (i.e. causing lysis) within the kidney cells (21, 108). In culture, 
COS-7 cells show adherent growth to glass and plastic surfaces. This cell line has been used 
extensively for transfection to produce recombinant proteins for molecular biology, biochemistry 
and cell biology experiments. This cell line expresses wild type p53 tumor suppressor. 
AML14.3D10 cells. The AML14.3D10 cell line is a subclone from the AML14 human 
myeloid leukemia cell line in 1992 from acute myeloid leukemia (8, 100). The cells are 
eosinophil-like and are inducible for eosinophil differentiation to become either neutrophil-like 
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cells when exposed to all-trans retinoic acid (ATRA) or monocyte/macrophage with vitamin D 
or phorbol esters (8). As it is known that human neutrophils exhibit a regulated PLD activity, the 
further study of PLD activity and regulation of PLD in neutrophil-like cells from ATRA-treated 
AML14.3D10 cells is, therefore, examined in this thesis to compare to MDA-MB-231 cancer 
cells.  
MCF7 cells. The MCF7 cell line is a breast cancer cell line obtained in 1970 from a 
female patient (85, 136). This cell line is characterized as differentiated mammary epithelium, 
which retained its ability to process estradiol via cytoplasmic estrogen receptors and the 
capability to form domes (25, 85, 136). Compared to MDA-MB-231 cells, MCF7 cells are less 
proliferative, less invasive and less metastatic (103). MCF7 cells express wild type p53 proteins. 
HL60 cells. The HL60 cell line is derived from the peripheral blood leukocytes of a 
patient with acute promyelocytic leukemia. This cell line can be differentiated with treatment of 
phorbol myristic acid (PMA), butyrate, dimethylsulfoxide (DMSO) or retinoic acid. Once 
differentiated, these cells become phagocytic, which is extensively used as a substitute for 
phagocytes in molecular biological and biochemical research.  This cell line is deficient of p53 
tumor suppressor due to major deletions of the TP53 gene. 
H1299 cells. The H1299 cell line is a human non-small cell lung carcinoma cell line 
derived from the metastatic lymph node (39). This cell line does not express p53 protein due to 
its homozygous partial deletion of the TP53 gene protein and do not express the tumor 
suppressor p53 protein (83) which partly account for their susceptibility to be more proliferative.  
Inhibitors 
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Apigenin. Apigenin (4,5,7,trihydroxyflavone) (Figure 6A) is a nonmutagenic 
bioflavonoid found in leafy plants with properties such as anti-inflammatory, anti-oxidant and 
anti-carcinogenic (54). Studies have shown that apigenin can reverse cyclosporine-induced 
damage, stimulate adult neurogenesis and inhibit CYP2C9, an enzyme responsible for the 
metabolism of many pharmaceutical drugs in the body (111, 118, 127). During signal 
transduction, apigenin has been shown to inhibit PKC and MAPK activity, extracellular signal 
regulated kinase (ERK) and phosphorylation of EGFR tyrosine kinase (80, 111, 116, 134, 143).  
Dr. Cambronero’s laboratory has previously shown the inhibitory effect of apigenin on JAK3 
kinase that led to reduced PLD2 activity and an associated lower cell invasion  in MTLn3 cells 
(48).   
5-Fluoro-2-indolyl des-chlorohalopemide (FIPI). FIPI (Figure 6B) is a pharmacological 
PLD inhibitor that inhibits PLD1 and PLD2 activity with great potency both in vivo (0.5 nM IC50) 
and in vitro (25 nM IC50) (19).  FIPI inhibits the catalytic activity of PLD and thus effectively 
blocks PA production (122). In addition, FIPI inhibits chemotaxis, F-actin cytoskeleton 
reorganization and cell spreading, which are regulated by PLD without interfering with the actin 
cytoskeleton, the cellular distribution of the proteins or access to its cofactor PIP2. 
The PA sensor 
For detection of endogenous PA using fluorescence microscopy, I used PA sensor. The 
PA sensor plasmid takes advantage of a 40-amino acid sequence found in Spo20 (Sporulation- 
specific protein 20) that binds to cell membrane phospholipids, particularly PA. Spo20 is a yeast 
protein required to the fusion of exocytic vesicles with the plasma membrane during yeast 
sporulation through its interactions with the SNARE complex (94-96). Spo has an inhibitory 
region that sequesters the protein in the nucleus (94, 133) and a positive regulatory region that 
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binds to phospholipids (including PA) in the cell membrane. This region contains an amphipathic 
helix with hydrophobic and positive charged faces. The initial report of a plasmid construction of 
the PA sensor in yeast, with the coding sequence of the PA binding domain (PABD) from 
Spo20p amino acids 51–91 was in Ref 142 (94). Cloning of the PABD in pEGFPC1 vector 
(Clontech) leading to pEGFP-Spo20PABD-wt for use in microscopy of mammalian cells and 
generation of the pEGFP-Spo20PABD-L67P mutant was performed in (146), where the authors 
show that PA is not present in cell membrane in resting cells but it becomes visible upon cell 
stimulation (PA is present in the nucleus of resting cells but that could be non-specific, no-PA 
related). Another use in mammalian cells with PLD inhibitor was reported in (122) and the first 
use in leukocytes and also R.E.D. analysis is in (37) indicating that the construct is cut by 
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Figure 6. Schematic structure of apigenin and FIPI.  
 
 
 
 
 
 
ApaLRI at the pUC origin (in addition, Age and DraII are one cut, Pst is a two-cut, and NCoI is a 
four-cut restriction enzyme). 
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HYPOTHESIS AND SPECIFIC AIMS 
Hypothesis 
 The MDA-MB-231 human breast cancer cell line is highly proliferative and metastatic, 
and also bears high PLD2 enzymatic activity (26) for reasons not well understood. I 
hypothesized that PLD2 plays an essential role in maintaining the high levels of proliferation that 
I observed in MDA-MB-231 cells. I specifically hypothesized that through enhanced activities of 
Fes and JAK3 tyrosine kinases, the PLD2 activity is enhanced.  
 To demonstrate this hypothesis, I developed a series of experiments with two Specific 
Aims: 
AIM 1: A novel pathway governing cell proliferation exists between Fes, JAK3, and PLD2, 
and is heightened in cancer cells. In this part, I would like to find out the cellular events that 
lead to abnormally upregulated PLD2 activity in MDA-MB-231 breast cancer cells. I 
hypothesized that the lipase activity in MDA-MB-231 cells is related to high tyrosine kinase 
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activity known to be elevated in cancer cells, and I set out to compare these transformed cells 
with untransformed cells. To demonstrate this, I used the MDA-MB-231 cells as the highly 
proliferative, transformed cell model and, and MCF10A as a model of untransformed, normal 
cells and studied the enzymatic and protein expression levels of the following proteins: JAK3, 
Fes and PLD2. I used site-directed mutagenesis to make JAK3, Fes and PLD2 mutants that 
facilitate my investigation of their interactions. I also measured the intracellular levels of the 
phospholipids PA and its interaction with JAK3 and Fes kinases in both cell lines. Finally, I 
conducted experiments to investigate the differential effects of JAK3, Fes and PLD2 activities on 
MDA-MB-231 cells compared to MCF10A cells. 
AIM 2: Serum deprivation confers a survival mechanism operating through a pathway 
involving EGFR/JAK3/PLD2 on the MDA-MB-231 cell line. As it is known that PLD2 can 
contribute to increased cell transformation upon epidermal growth factor (EGF) stimulation of 
cells and that MDA-MB-231 cells bear elevated PLD activity, I used these cells to study how the  
the highly invasive phenotype are regulated and if this regulation is PLD2-dependent under 
conditions of serum deprivation. The starvation serum contains Dulbecco’s Modified Eagle 
Media (DMEM) or Iscove’s Modified Eagle Media (IMEM) depending on the cells types, 
together with 0.5% bovine serum albumin (BSA). Application of starvation serum mimics the 
environments a cancer cell might encounter at the center of a tumor where there is insufficient 
nutrient.  I also examined other cell types including COS-7, MCF7, H1299 and differentiated 
HL60 (dHL60). Further, I used the small molecule inhibitor apigenin to test if it could counteract 
the highly invasive phenotype of these breast cancer cells with a future potential therapeutic 
benefit. 
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V. MATERIALS AND METHODS 
Materials 
Dulbecco’s Modified Eagle Media (DMEM) and Iscove’s Modified Eagle Media 
(IMEM) were from Mediatech (Manassas, VA); Mammary Epithelial Cell Growth media was 
from Cell Applications, Inc. (San Diego, CA); Lipofectamine and Plus reagent were from 
Invitrogen (Carlsbad, CA); siQuest transfection reagent was from Mirus (Madison, WI); 
matrigels were from BD Biosciences (San Jose, CA); hematoxylin was from Ricca Chemical Co. 
(Arlington, TX); apigenin and FIPI were from Sigma (St. Louis, MO); CAY10594 was from 
Cayman Chemical (Ann Arbor, MI); protein G agarose beads, mouse anti-PLD2 IgG antibody 
(SKB2), purified recombinant human JAK3, purified recombinant human Fes and the Fes 
substrate peptide (poly(Glu4-Tyr) biotin-conjugated) were from Millipore (Billerica, MA); 
JAK3tide synthetic peptide substrate was from Anaspec (Fremont, CA); [3H]-butanol was from 
American Radiolabeled Chemicals (St. Louis, MO); [32P]-γATP was from Perkin-Elmer 
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(Waltham, MA); ECL reagent was from GE Healthcare (Piscataway, NJ); rabbit anti-JAK3 and 
rabbit anti-Fes IgG antibodies were from Cell Signaling (Danvers, MA); rabbit anti-PLD2 (H-
133) IgG antibody and donkey anti-rabbit TRITC IgG antibody were from Santa Cruz (Santa 
Cruz, CA); and si-Neg, siFES and siJAK3 were from Applied Biosystems (Foster City, CA).  
Methods 
Cells and cell culture. MDA-MB-231, COS-7 and HL-60 cells were obtained from ATCC. 
MCF-7, H1299 and MCF10A cells were a gift from Dr. Steven Berberich (Wright State 
University) and AML-3D10 cells were a gift from Dr. Michael Baumann (Wright State 
University). MCF-7, MDA-MB-231, H1299 and COS-7 cells were cultured in DMEM 
supplemented with 10% (v/v) fetal bovine serum (FBS), while MCF10A cells were cultured in 
Mammary Epithelial Cell Growth with 0.4% (v/v) bovine pituitary extract, 10-7% (w/v) 
epidermial growth factor, 5x10-4% (w/v) insulin, and 5x10-5% (w/v) hydrocortisone. 
Promyelocytic leukemic HL-60 cells and AML-3D10 cells were grown at 37 oC in a 5% CO2 
incubator in Iscove’s Modified Eagle’s Media (IMEM) + 20% (v/v) heat-inactivated fetal bovine 
serum, 2 mM L-glutamine. Cell density was maintained between 0.1 and 1.0x106/ml. The 
plasmids used in these experiments were as follows: pcDNA3.1-mycPLD2-WT, pcDNA3.1-
mycPLD2-Y169F, pcDNA3.1-mycPLD2-Y179F, pcDNA3.1-mycPLD2-Y415F, pCMV6-XL4-
Fes-WT (Origene, Rockville, MD), pME1S-JAK3-WT (a kind gift from Dr. John O’Shea, NIH) 
and pEGFP-Spo20-PABD-WT (a kind gift from Dr. Michael Frohman, SUNY). The following 
mutant plasmids were prepared by site-directed mutagenesis by Mutagenex (Hillsborough, NJ): 
pCMV6-XL4-Fes-K590E (kinase-dead) and pCMV6-XL4-Fes-E469K/E472K (SH2 deletion 
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mutant) ; pME1S-JAK3-K855A (kinase-dead) and pME1S-JAK3-R402K/R403K (SH2 deletion 
mutant) .  
Cell transfection and gene silencing. Transfections were performed using ~2 µg of plasmid 
DNA, 5 µl Lipofectamine (Invitrogen, Carlsbad, CA) and 5 µl Plus reagent (Invitrogen) in Opti-
MEM medium (Invitrogen) in sterile glass test tubes, per the manufacturer’s protocol. MDA-
MB-231 and MCF10A cells were transfected for 3 h and were washed and refed with prewarmed 
complete medium. After 36 h, cells were harvested for their respective experiment.  
Fes and JAK3 expression in cells was downregulated using small interfering RNA 
(siRNA) in combination with the siQuest transfection reagent (6 µl). Then up to 300 nM siRNA 
was used in the appropriate complete cell culture growth media and applied to the cells. Double-
stranded RNA (dsRNA) was from Applied Biosystems (Foster City, CA) as “select validated.” 
For JAK3, I used a siRNA that targeted exon 19 [locus s7653; sense, 5′-
GUAUCGUGGUGUCAGCUAUd(TT)-3’]. For Fes, we used siRNAs that targeted exons 16 and 
18 [locus s5113; sense, 5’- CCUCAGCAAUCAGCAGACAd(TT)-3’]. A negative control for 
siRNA was also from Applied Biosystems. Neg-siRNA2 is a 19-bp scrambled sequence with 3′-
dT overhangs (sequence not disclosed by manufacturer). The cells were allowed to incubate with 
the siRNA in complete medium (minus antibiotics) for 3-4 days before being harvested.  
Detection of Intracellular PA Using a GFP-based Sensor. The yeast (Spo20p) soluble N-
ethylmaleimide-sensitive factor attachment protein receptor (SNARE) PA binding domain 
(wtPABD) was cloned in a pEGFPC1 vector (Clontech) and denoted “pEGFP-Spo20PABD-
WT”. The origin of the coding sequence of Spo20p amino acids 51–91 was reported in 
Nakanishi et al., who amplified it by PCR using BBO5 and PDO2 as primers and pRS306-
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SPO20pr-SPO20 as a template and introduced XhoI and XbaI sites. This construct is cut by 
ApaLRI at the pUC origin (in addition, AgeI and DraII are onecut, PstI is a two-cut, and NcoI is 
a four-cut restriction enzyme). The wild type PA binding sensor has been characterized.  The 
intensity of green light (550nm) observed in the fluorescent microcopy is correlated to the 
amount of PA present in the cell, after cells are stimulated by agonist EGF. PA sensor-loaded 
cells can also display differences in PA subcellular localization. 
MCF10A or MDA-MB-231 cells were transfected with 1.5 µg wild type PA sensor 
and/or a combination of 1.5 µg Fes-WT and/or 1.5 µg PLD2-WT and were grown on glass 
coverslips inside 6-well tissue cultures plates. Two days post-transfection, fresh media 
containing no serum was added to the dishes, and cells were incubated with exogenous PA. After 
15 min of stimulation, the medium was aspirated and cells were washed three times with 
phosphate-buffered saline to remove any traces of extracellular PA. Cells were fixed with 4% 
paraformaldehyde, permeabilized in 0.5% Triton X-100 in phosphate-buffered saline (PBS), 
blocked in 10% fetal calf serum (FCS) in 0.1% Triton X-100 in PBS, (if relevant, probed with 
either rabbit anti-Fes or rabbit anti-PLD2 (H-133) IgG antibodies and then donkey anti-rabbit 
TRITC IgG antibody), mounted onto glass microscope slides using VectaShield mounting media 
and imaged using the FITC channel (DAPI was also included to visualize the nucleus). Cells 
were examined on a Nikon Eclipse 50i fluorescence microscope and photographed (SPOT 
camera; Diagnostic Instruments) by consecutive exposure using green, red and blue filters with a 
100x (numerical aperture 0.9) OIL objective. 
Cell invasion assays. Cells were serum-starved for 2 hours and resuspended at a concentration 
1.5 x 106 cells/ml in chemotaxis buffer (DMEM + 0.5 % bovine serum albumin for MDA-MB-
231, H1299 and MCF-7 cells or HMEM + 0.5 % bovine serum albumin for MTLn3 cells).  Two 
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hundred µl cells were applied to the upper chambers of 8 µm PET Matrigels (24-well format) 
with a 6.5 mm diameter membrane (Figure 7).  Final concentration of chemoattractant used was 
0 or 3 nM EGF in 500 µl of chemotaxis buffer placed in the lower wells of 24-well plates.  Cell 
invasion assays were incubated for 6 hr (MDA-MB-231 and H1299) or overnight (MTLn3 and 
MCF-7) at 37 oC in a humidified 5 % CO2 cell culture incubator.  Cells were scraped from the 
Matrigel insert and were then stained for 1 hr in hematoxylin at room temp to visualize cells that 
invaded the Matrigel.  The number of cells that migrated through the Matrigel to the bottom 
surface of the insert was calculated by counting 3 fields of cells using a 20x objective and a 10x 
ocular. 
 
.   
 
 
 
Figure 7. Schematic representation of Matrigel assay for cell invasion analysis. 
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Cell proliferation assay. Cells were plated into 24-well plates prior to use. Duplicate wells were 
untreated or treated with 300 nM siRNA for 0, 12, 24, 36, 38, 60 or 72 hr or were untransfected  
or transfected with 1.5 µg of various PLD2, Fes or JAK3 plasmid constructs for 60 hr. After 
incubation, cells were washed 2x with PBS and trypsinized and final volume brought up to        1 
ml/well using complete DMEM containing 10% FCS. Fifty µl of trypan blue was added to each 
cell sample and viable cells counted/ml cells. 
Co-immunoprecipitation and Western-Blot Analyses. After transfection, cells were harvested and 
lysed with Special lysis buffer (5 mM HEPES, pH 7.8, 100 µM Sodium orthovanadate and 0.1% 
Triton X-100). The lysates were sonicated and treated with 1 µl monoclonal antibody for the 
respective protein and 20 µl Protein G agarose beads and incubated at 4°C for 4 h. After 
incubation, the immunoprecipitates were washed with LiCl wash buffer (2.1% LiCl, 1.6% Tris-
HCl, pH 7.4) and NaCl wash buffer (0.6% NaCl, 0.16% Tris-HCl, 0.03% EDTA, pH 7.4), 
respectively, and sedimented at 12,000 × g for 1 min. Using different types of salts (LiCl and 
NaCl here) removes effectively non-specific protein interaction with the agarose beads. Lithium 
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is also soluble in buffers containing high amounts of SDS and is hence used as a component of 
wash buffer. The resulting pellets were then analyzed using SDS-PAGE and Western-blot 
(W.B.) analyses.  
For Western-blot analyses with or without immunoprecipitation, ~500 or 100 µg cell 
lysates, respectively, were separated using SDS-PAGE and then transferred onto Immobilon-P 
(PVDF) membrane for 1 hr at 400 mA. PVDF membranes were blocked in 5% bovine serum 
albumin (BSA), 0.5% Tween-20 in Tris-buffered saline (TBS-T) for 1 hr at room temp, probed 
with primary IgG antibodies overnight at 4 oC and then probed with secondary IgG HRP-
conjugated antibodies for 1 hr at room temp. PVDF membranes were then exposed to ECL 
reagents and western-blot reactions were detected using autoradiography film. 
PLD activity assay. Cell lysates were processed for PLD activity in PC8 (1,2-dioctanoyl-sn-
glycero-3-phosphocholine) liposomes and [3H]n-butanol beginning with the addition of the 
following reagents (final concentrations): 3.5 mM PC8 phospholipid, 1 µM PIP2, 45 mM HEPES 
(pH 7.8), and 1.0 µCi [3H]n-butanol in a liposome form, as indicated in ref. (31) to accomplish 
the transphosphatidylation reaction of PLD. Samples were incubated for 20 min at 30 oC with 
continuous shaking. As previously stated in our lab (4) synthesis of phosphotidyl butanol (pBut) 
is linear in the first 20 min and only begin to reach plateau at 30 min. Addition of 0.3 ml ice-cold 
chloroform/methanol (1:2) stopped the reactions. Lipids were then isolated and resolved by thin 
layer chromatography. The amount of [3H]-PBut that co-migrated with PBut standards (Rf=0.45-
0.50) was measured by scintillation spectrometry. 
JAK3 and EGFR Kinase Assay. Samples containing 2 x 106 cells were either mock-treated or 
treated with 3 nM EGF for an 14 min in a 37 oC water bath with vigorous shaking. After 
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stimulation, cells were sedimented, washed and finally lysed via sonication in 20 µl SLB 
containing protease inhibitors. Lysates were incubated in the presence of the following final 
concentration of each: 4 mM MOPS, pH 7.0, 15 mM MgCl2, 1 mM EGTA, 0.2 mM Na 
Orthovanadate, 0.2 mM DTT, 1 µCi [32Pγ]-ATP, 100 µM cold ATP and 42 µM JAK3tide 
substrate to yield a 40 µl total kinase reaction volume. Reactions were incubated at 30 oC for 20 
min ( tested in our lab that the kinase reaction does not reach plateau at 20-min time span) and 
stopped by spotting 20 µl reactions onto 2 x 2.5 cm2 pieces of P81 Whatman filter paper for 
duplicate determinations. After filter papers were dry, each was washed in cold running water for 
5 min total. Filters were dried and individual filters placed into scintillation vials containing 
Scintiverse II (Fisher) liquid scintillation cocktail. All samples were counted in a Beckman LS 
6000TA liquid scintillation counter using the [32P] protocol for 1 min each. Results were 
quantified as DPMs and expressed in terms of percent over control. 
FES Kinase Assay. In the in vitro kinase assay, the phosphoacceptor peptide substrate was the 
FES substrate peptide: Poly (Glu4-Tyr) biotin conjugated (Millipore) in freshly-prepared kinase 
buffer (8 mM MOPS, pH 7.2, 9 mM MgAc, 30 µM Na2VO3, 5 mM p-nitrophenyl phosphate, 1 
mM EDTA, 2 µM cAMP-dependent kinase inhibitor, 0.420 mCi [γ-32P]ATP (7 nM), and 100 
µM unlabeled ATP). To initiate the phosphotransferase reaction, aliquots (20 µl) of kinase buffer 
containing the Fes substrate peptide were mixed 1:2 (v/v) with the cell lysates (~20 µg protein). 
The reaction was carried out at 37 oC for 10 min (tested in our lab so the kinase reaction does not 
reach plateau at 10 min time span) in a tube rotisserie and terminated by adding 5 µl of 3% 
phosphoric acid, and blotting 30 µl of the reaction mixture onto SAM-2 biotin capture 
membranes (Promega). Membrane squares were extensively washed with methanol, water, dried, 
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and counted for radioactivity. Positive controls used recombinant fully-active FES (Millipore). 
Negative controls were run in parallel with no FES substrate peptide.  
PIP2 and PA liposome preparation. The PA utilized in this work was a cell membrane soluble 
form, named “DOPA” (1,2-dioleoyl-sn-glycero-3-phosphate; Avanti Polar Lipids, Alabaster, 
AL) and was prepared by resuspending 1 mg DOPA in 1.4 ml liposome buffer (1× PBS plus 
0.5% bovine serum albumin [BSA], pH 7.2). The solution was diluted in low bicarbonate 
DMEM plus 10% fetal calf serum (FCS) to achieve an intermediate stock of 1 mM and then 
sonicated at medium strength for 20 bursts of 5 s each while on ice. Intermediate dilutions were 
made in Hanks’ balanced buffer plus 0.5% BSA, pH 7.35, and applied to the cells. PIP2 was 
prepared by drying under a N2 stream to evaporate the CHCl3 and resuspended in liposome 
buffer, following the protocol as indicated above for PA. 
Statistical Analysis. Data are presented as mean + SEM. The difference between means was 
assessed by the Single Factor Analysis of Variance (ANOVA) test. Probability of p<0.05 
indicated a significant difference. 
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VI. RESULTS 
AIM 1: A novel pathway governing cell proliferation exists between Fes, JAK3, and PLD2, 
and is heightened in cancer cells.  
A. A differential biochemical activity of Fes, JAK3 and PLD2 in non-transformed versus 
transformed cells 
To begin the research project that led to this thesis, I measured the endogenous activity of 
JAK3, Fes and PLD2 in normal (MCF10A epithelial cells) and cancer cells (MDA-MB-231). 
Figure 8A,C,E shows that the MDA-MB-231 cancer cells possess greater endogenous JAK3, Fes 
and PLD activities when compared to the non-transformed MCF10A cells. I also investigated the 
activities of JAK3, Fes and PLD2 in a range of cell types (results not shown) and found a similar 
pattern for catalytic activities, i.e. the kinase and lipase activities are higher in transformed cells 
(MCF10A breast cancer cells, eosinophilic AML14.3D10 cells, leukemic HL60 cells and ) than 
in untransformed cells (kidney epithelial fibroblast COS7 cells).  
33 
 
Figure 8B,D,F shows the endogenous expression of each of the proteins in untransformed 
MCF10A and MDA-MB-231 cancer cells. PLD2 level is significantly higher in the cancer cells 
than in MCF10A cells (Figure 8F). The protein levels of JAK3 in MDA-MB-231 cells are higher 
but to a lesser extent than in MCF10A cells (Figure 8B).  I also found that the Fes protein level is 
approximately similar in MCF10A cells to those in MDA-MB-231 cells (Figure 8D). Therefore, 
the reason of significant higher JAK3 and Fes kinase activities in MDA-MB-231 cells is highly 
unlikely to be a result of higher protein expression. 
 
Figure 8. Endogenous JAK3, FES, and PLD2 activity levels in untransformed and 
transformed cells.  JAK3 (A), Fes (C) and PLD2 (E) activities were measured in MCF10A and 
MDA-MB-231 cell lysates starting from similar number of cells per sample and then adjusting 
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for similar protein levels per sample. All 3 activities are elevated in MDA-MB-231 cancer cells 
compared to non-transformed MCF10A cells. Results in this figure are the means + SEM from at 
least 3 independent experiments conducted in duplicate. The symbol * denotes statistically 
significant (p<0.05) differences (increases) between samples and controls.  Western blot analysis 
of endogenous JAK3 (B), Fes (D) and PLD2 (F) proteins (~100 µg/lane) in non-transformed 
MCF10A and transformed MDA-MB-231 cancer cell lines with actin expression included as 
protein loading controls. 
 
B. JAK3, Fes and PLD2 mutants are designed and characterized.  
Mutant forms of JAK3, Fes and PLD2 were generated (Figure 9A) to study to what 
extent tyrosine kinases JAK3 and Fes may regulate PLD2. The catalytic sites were targeted on 
each kinase to generate kinase dead mutants JAK3-K855E (JAK3-KD). SH2 binding deficient 
forms of JAK3 (JAK3-SH2-L-i) and Fes (Fes-SH2-i) were also generated, which target residues 
R402/R403 in the SH2-like domain of JAK3 and residues E469/E472 in the SH2 domain of Fes. 
Regarding PLD2, Two tyrosine residues Y169 and Y179 situated within the YxN motif that is 
recognized by SH2-bearing proteins and Y415 which is essential for JAK3 binding (47) were 
targeted to generate SH2-binding deficient mutants PLD-Y169F and PLD-Y179F and          
JAK3-binding deficient mutant PLD-Y415F. Each mutant is generated by point 
mutation/mutations using site-directed mutagenesis. 
The left panels of Figure 9B-D demonstrate the expression levels of the engineered 
plasmid constructs in Western blot analysis, all of which showed similar expression. It is also 
shown here the impact of mutations on enzymatic activities (Figure 9B-D, right panels). Lysine 
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to Glutamic Acid mutations for both JAK3 (K855E) and Fes (K590E) in their respective kinase 
domain rendered the respective kinases to low basal level. Double-point mutations in the SH2-
like and SH2 domains of JAK3 and Fes, respectively, do not affect JAK3 activity, but affect Fes 
activity to some extent as the SH2 domain has been implicated for optimal Fes activity (35). It is 
still viable for its study since the Fes-SH2-i mutant maintained most Fes activity. 
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Figure 9. Analysis of wild type and mutant JAK3, Fes and PLD2 proteins. (A) The sites of 
mutagenesis in JAK3 are indicated, including R402 and R403, which are important for ligand 
binding and K855 which is important for kinase activity. Fes has a Tyr kinase domain and a Src 
homology 2 (SH2) domain that bind to ligands and enhance kinase activity. The F-BAR and FX 
domains are involved in phospholipid binding, membrane localization and kinase activity. The 
sites of mutagenesis in Fes are indicated including E469 and E472 important for ligand binding  
 
 
 
 
 
(Figure 9 legend continued) 
and K590 essential for kinase activity. The sites of mutagenesis in PLD2 are indicated including 
Y169 and Y179 which are important for binding of SH2-containing proteins and Y415 which is 
important for JAK3 binding. (B-D) Western blot analyses of expression of recombinant wild-
type and mutant JAK3, Fes, and PLD2 proteins (~100 µg/lane), respectively. These experiments 
were conducted to function as controls to demonstrate comparable expression of each protein 
and their corresponding mutants in subsequent experiments that used the recombinant proteins.  
JAK3-K855E and Fes-K590E are both kinase-dead mutants. JAK3-R402K/R403K and Fes-
E469K/E472K are JAK3 SH2-like (JAK3-SHLi) and Fes SH2 (Fes-SH2i) domain mutants, 
respectively. PLD2-Y169F and -Y179F are SH2 binding domain mutants (PX domain). PLD2-
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Y415F is a tyrosine mutant that prevents phosphorylation and activation through JAK3.  Kinase 
and lipase activities in vitro of cell lysates that overexpress the three proteins of interest used in 
this study (JAK3, Fes and PLD2).  Results in this figure are the means + SEM from at least 3 
independent experiments conducted in duplicate. The symbols * and # denote statistically 
significant (p<0.05) differences (increases or decreases, respectively) between samples and 
controls. 
D. JAK3 kinase regulates PLD2 in both transformed and transformed cells 
 Our lab has previously demonstrated phosphorylation of certain tyrosine residues within 
PLD2 upon stimulation of cells (49). To examine whether this phosphorylation occurred due to 
JAK3 activity, I devised a series of experiments. Figure 10A left panel demonstrates the impact 
of silencing JAK3 in MDA-MB-231 or MCF10A cells. Silencing JAK3 decreased lipase activity 
in MDA-MB-231 cells, but increased PLD activity in MCF10A cells, suggesting a positive role 
of JAK3 on PLD2 activity in the cancer cells but a negative one in MCF10A cell. The right panel 
is a control that shows effective silencing of JAK3 using siRNA.  
Figure 10B demonstrates JAK3-WT or JAK3 mutant plasmid constructs expressed in 
MCF10A or MDA-MB-231 cells and the resulting effect of the expression of these constructs on 
PLD2 activity in vivo. JAK3-WT decreased lipase activity to a moderate degree in MCF10A 
cells but had a significant positive effect in cancer cells. The kinase dead mutant JAK3-KD 
reduced PLD2 activity significantly suggesting the possibility of JAK3 phosphorylation and 
activation of PLD2. Even though we are aware of the possibility that more rapidly dividing 
MDA-MB-231 cells take up more plasmid so higher percentage of cells are transfected than 
MCF10A cells, we have seen that protein expression in both cell types are approximately similar.  
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Figure 10C demonstrates the effect that increasing amounts of DNA constructs for JAK3 
or JAK3 and PLD2 have on PLD2 activity in vivo in MDA-MB-231 cells. The results are 
consistent with the finding that JAK3 acts as a positive regulator of PLD2 activity in the cancer 
cells. Recombinant purified JAK3 was also utilized and induced a significant increase in PLD2 
activity after incubation with either MDA-MB-231 cells or recombinant purified PLD2 proteins.  
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Figure 10. Effect of JAK3 on PLD2 activity in non-transformed versus transformed cells.  
(A) Effect of silencing JAK3 on endogenous PLD activity in MCF10A and MDA-MB-231 cells 
(300 nM siRNA per transfection; 4 day-silencing). MCF10A cells saw a slight increase in PLD2 
activity with siJAK3, while MDA-MB-231 cells saw a significant decrease in siJAK3.  Results 
in this figure are the means + SEM from at least 3 independent experiments conducted in 
duplicate. The symbols * and # denote statistically significant (p<0.05) differences  
 
 
 
 
 
 
 
 
(Figure 10 legend continued) 
(increases or decreases, respectively) between samples and controls. (Inset) Evidence of JAK3 
silencing using short interfering RNA (300 nM siRNA per transfection; 4 day-silencing) in 
MCF10A and MDA-MB-231 cells. Western blots were performed to determine that JAK3 was 
effectively silenced (~100 µg/lane). Actin is shown as an equal loading control. (B) JAK3-WT or 
JAK3-KD were each overexpressed in MCF10A and MDA-MB-231 cells, and PLD activity was 
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measured from the resulting cell lysates. Overexpression of JAK3-WT and Fes-WT modestly 
increased PLD activity in MCF10A cells, while there was a much more significant increase in 
PLD activity in MDA-MB-231 cells. (C) Increasing JAK3-WT overexpression has a positive 
effect on both endogenous and overexpressed PLD activities in MDA-MB-231 cancer cells in 
vivo and in vitro, which can be reversed in the presence of the tyrosine kinase inhibitor, 
apigenin. 
The isoflavone, apigenin, was also used as a JAK3 inhibitor which abrogated the positive effect 
of JAK3 on PLD2 activity. 
E. Fes modulate PLD2 activity differently in transformed cells compared to untransformed 
cells due to differential interaction sites on PLD2 
As it was previously known that Fes possesses an SH2 domain (Figure 4), I reasoned that 
this SH2 could interact with PLD2 at the two tyrosine residues located within the PX domain of 
PLD2. Using the Fes-SH-i mutant, together with the Fes-KD mutant and PLD2-YF mutants, I 
examined the association between Fes and PLD2. In Figure 11A left panel, PLD2 activity is 
assayed when Fes is silenced in both cell types. Fes depletion has a negative impact on PLD2 
activity in both the transformed and untransformed cells. Such negative impact is more 
significant in MDA-MB-231 cells than in MCF10A cells. Fes is therefore a positive regulator in 
both cell types but has a greater positive effect on the cancer cells. The right panel is a control 
that shows effective silencing of Fes using siRNA.  
In Figure 11B, I demonstrate that PLD2 activity in MDA-MB-231 cells is affected by 
deficiency of the SH2 domain and loss of kinase activity in Fes. On the other hand, in MCF10A 
cells, loss of Fes kinase activity reduced PLD2 activity to basal level while overexpression of 
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SH2-inactive Fes mutant did not affect PLD2 activity. MCF10A cells showed a marked decrease 
in PLD2 activity upon transfection with Fes-WT. The kinase-inactive Fes (K590E) displayed a 
decrease in lipase activity in both cell lines. 
I next examined how lipase activity was affected by mutations in PLD2 in context with 
wild-type Fes (Figure 11C). With the presence of overexpressed Fes, both PLD2-Y169F and 
PLD2-Y179F rendered PLD2 activity to basal level, while overexpression of PLD2-Y415F  
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Figure 11. Effect of Fes on PLD2 activity in non-transformed versus transformed cells.  (A)  
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(Figure 11 legend continued) 
Effect of silencing Fes on endogenous PLD activity in MCF10A and MDA-MB-231 cells (300 
nM siRNA per transfection; 4 day-silencing). MCF10A cells saw a slight increase in PLD2 
activity with siFes, while MDA-MB-231 cells saw a very significant decrease in siFes.  Results 
in this figure are the means + SEM from at least 3 independent experiments conducted in 
duplicate. The symbol # denotes statistically significant (p<0.05) decreases between samples and 
controls. (Inset) Evidence of Fes silencing using short interfering RNA (300 nM siRNA per 
transfection; 4 day-silencing) in MCF10A and MDA-MB-231 cells. Western blots were 
performed to determine that Fes was effectively silenced (~100 µg/lane).  Actin is shown as an 
equal loading control. (B) PLD2 activity in MCF10A and MDA-MB-231 cells over expressing 
Fes-WT, Fes-KD, or Fes-SH2 deficient plasmids (2 µg DNA per transfection; 2 day-
transfection). MDA-MB-231 cells show a significant increase with Fes-WT transfection, an 
effect which was abrogated with SH2 mutant expression. (C) PLD2 activity in MCF10A or 
MDA-MB-231 cells transfected with PLD2-WT, Fes-WT or both or co-transfections of PLD2-
WT or its mutants, PLD2-Y169F, PLD2-Y179F or PLD2-Y415F (2 µg DNA per transfection; 2-
day transfection) with Fes-WT. The decrease in PLD activity of MDA-MB-231 cells that 
overexpressed both Fes-WT and the PLD2 mutants Y169F and Y179F demonstrate a key role in 
regulating the Fes kinase activity through these two residues on PLD2 in transformed cells. For 
MDA-MB-231 cells, a decrease occurs when Fes-WT and PLD2-Y415F mutants were both 
overexpressed suggesting the residue 415 on PLD2 is important for PLD2 interaction with Fes. 
The symbols * and # denote statistically significant (p<0.05) differences (increases or decreases, 
respectively) between samples and controls.  (D) PLD2 and Fes form a protein:protein complex. 
Panels demonstrate co-immunoprecipitation of overexpressed PLD2 and Fes proteins in both 
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(Figure 11 legend continued) 
MCF10A and MDA-MB-231 cells. Immunoprecipitations were performed with either rabbit 
anti-myc (PLD2) or rabbit anti-Fes IgG antibodies bound to Protein G agarose beads, and after 
SDS-PAGE, the resulting western blots were probed with either rabbit anti-myc or rabbit anti-
Fes IgG antibodies, respectively.  Anti-myc antibodies were used for immunoprecipitations, and 
the anti-Fes antibodies were used to probe the western blots (top panels). Fes was detected at the 
native molecular weight of ~95 kDa (second panels from top).  Equal protein loading controls 
were detected using rabbit α-actin antibody (second panels from bottom). Negative controls 
using IgG antibody for co-immunoprecipitations are included in the bottom panels for each cell 
line. Binding of Fes-SH2 mutant to PLD2 is decreased in MDA-MB-231 cancer cells compared 
to MCF10A cells. Results in this figure are the means + SEM from at least 3 independent 
experiments conducted in duplicate. 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plasmid did not affect PLD2 activity. This in combination with the finding in Figure 4B that the 
Fes-SH2-i mutant knocked down PLD2 activity to basal level, suggesting the interaction 
between Fes and PLD2 in MDA-MB-231 cells is through the SH2 domain in Fes and the SH2-
binding motif (where Y169 and Y179 are located) of PLD2. In contrast, when Fes was co-
transfected, deficient in SH2-bearing protein binding in PLD2 (PLD2-Y169F and PLD2-Y179F) 
did not affect the lipase activity while mutation at Y415 residue affected the lipase activity. 
Taken together the finding that Fes-SH2-i mutant does not affect PLD2 activity in MCF10A cells 
(Figure 11B), the interaction between PLD2 and Fes is mediated by PLD2-Y415 and site on Fes 
other than the SH2 domain.  
Figure 11D shows an anti-PLD2 immunoprecipitation followed by Western blotting with 
anti-Fes antibodies. The presence of a band at the corresponding molecular weight marker for 
Fes denotes the presence of Fes:PLD2 binding in both MCF10A and MDA-MB-231 cells. 
Furthermore, when I utilized the SH2-inactive Fes-SH2-i mutant along with endogenous PLD2, 
Fes expression was reduced in MDA-MB-231 cells. This indicates that Fes binds to PLD2    
SH2-binding motif through Fes’s SH2 domain in the cancer cells. In contrast, in MCF10A cells, 
a slightly darker band shows a stronger interaction between Fes-SH2-i and endogenous PLD2 
illustrating that the SH2 domain of Fes is not important in PLD2 binding in untransformed cells. 
The reason of the presence of stronger binding between Fes-SH2-i mutant and PLD2 will be 
discussion in the later section.  
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D. Fes is differentially modulated by phospholipids in untransformed and transformed 
cells 
As PLD2’s major enzymatic activity generates PA, I wanted to examine if there is any 
interaction between PA and the two kinases under investigation. For this, I used a PA sensor 
which is a plasmid (Figure 12A) containing a 40-amino acid sequence found in yeast Spo20 
(Sporulation-specific protein 20) that binds to cells membrane phospholipids, particularly PA. 
Cloning of the PA binding domain (PABD) in pEGFPC1 vector leads to pEGFP-Spo20PABD-
wt for use in microscopy of mammalian cells. Therefore, The PA sensor can be transfected to 
detect PA levels in fixed cells. The intensity of GFP (in the FITC channel of a fluorescence 
microscope) correlates with the existing amount of PA. 
 In my study, I transfected MDA-MB-231 and MCF10A cells with PA only or PA in 
combination with Fes coupled with EGF stimulation (Figure 12A). The upper panels in Figure 
12A show that there are more endogenous PA in MDA-MB-231 cells than in MCF10A cells. In 
addition, PA is nuclear in MCF10A cells while perinuclear in MDA-MB-231 cells. After EGF 
treatment, PA is translocated to cytoplasm in both cell types (Figure 12A lower panels). A 
significant increase in the endogenous PA level was seen upon Fes co-transfection in MDA-MB-
231 cells and a moderate one in MCF10A cells (Figure 12B upper panels). Further increase of 
PA level is also seen with EGF treatment in both cell lines (Figure 12B lower panels). Again, 
both the nuclear PA in MCF10A cells and the perinuclear PA in MDA-MB-231 cells 
translocated to the cytoplasm where it is active after EGF stimulation. 
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Figure 12. Interplay between phosphatidic acid (PA) and Fes and JAK3 kinases. (A) 
MCF10A and MDA-MB-231 cells were plated onto glass coverslips and then transfected with 1 
µg Fes plasmid in combination with a 1 µg of the PA sensor (EGFP-based) plasmid. Two-days  
48 
 
 
 
 
 
 
(Figure 12 legend continued) 
post-transfection cells were serum-starved for 2 hr and then stimulated with 3 nM EGF for 15 
min.  Cells were fixed onto coverslips with 4% paraformaldehyde, permeabilized with 0.5% 
Triton X-100 in PBS and then blocked with 0.1% Triton X-100 in PBS.  Coverslips were probed 
with 1:200 Mouse anti-Fes IgG antibody and then Goat anti-mouse TRITC IgG antibody to 
visualize Fes staining. Green denotes the EGFP-tagged PA sensor.  Blue denotes DAPI staining 
of the nucleus. Upper row, staining of the PA sensor (FITC) and nuclei (DAPI) only in cells in 
the absence of EGF. Lower row, staining of the PA sensor (FITC) and nuclei (DAPI) only in 
cells in the presence of EGF. (B) Upper row, staining of the PA sensor (FITC) and nuclei (DAPI) 
in the presence of Fes-WT (TRITC) in the absence of EGF.  Lower row, staining of the PA 
sensor (FITC) and nuclei (DAPI) in the presence of EGF.  (C) Effect of 100 nM lipids (PA, PIP2 
or PC) on recombinant JAK3 and Fes activities in vitro. (D) Differential effect of PA (DOPA, 
PA in a di-oleoyl or membrane-soluble form) on endogenous Fes activity of MDA-MB-231 and 
MCF10A cells. Results in this figure are the means + SEM from at least 3 independent 
experiments conducted in duplicate. The symbols * and # denote statistically significant (p<0.05) 
differences (increases or decreases, respectively) between samples and controls. 
49 
 
I next investigated the effect of addition of the phospholipid PA (The product of PLD2 
enzymatic activity) on Fes and JAK3 kinase activities from either cell lysates or from whole cells 
in the first part (Figure 12C). Cell lysates containing Fes or JAK3 proteins were incubated with 
PA and were then used to measure Fes and JAK3 activities. PIP2 is another phospholipid known 
to function as an intracellular messenger. PC was used as a control in these experiments. PA 
significantly activated Fes activity in the cell lysates. I also observed that PIP2 activates Fes, 
which is a novel finding. I have seen previously that PIP2 acts through 1-phosphatidylinositol-4-
phosphate 5-kinase (PI5K; also activated by PA) and is also able to stimulate other proteins such 
as WASp (63).  Despite the change in Fes activity, no change was detected in kinase activity of 
JAK3 in the presence of PA as well as PIP2. In Figure 12D, I examined Fes kinase activity in 
whole cells upon treatment with PA. I saw an increase in Fes activity in MDA-MB-231 cells, but 
found no significant effect on MCF10A cells. 
E. JAK3 and Fes regulate each other 
To examine the interaction between Fes and JAK3, I utilized siRNA for JAK3. In Figure 
13A, I examined the effect of siJAK3 on Fes activity in a broad range of cell lines. All cells 
tested except COS-7 cells showed that JAK3 has a positive effect on Fes activity. Figure 13B 
demonstrates the effect of overexpressing Fes on JAK3 activity. In both MCF10A and MDA-
MB-231 cells, JAK3 activity is up-regulated by Fes expression but at a greater extent in the 
latter. Figure 13C examines Fes activity following JAK3 overexpression. Fes activity was 
augmented in MDA-MB-231 cells but decreased in MCF10A cells upon JAK3 transfection. 
Taken together, the kinases showed influences on each other, with JAK3 having a positive 
impact on Fes in both cell types and Fes has a positive impact on MDA-MB-231 cells but a 
negative one on MCF10A cells. 
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Figure 13. Interaction between JAK3 and Fes kinases. (A) Fes activity in non-transformed 
MCF10A and COS-7) and transformed (MDA-MB-231, MCF-7, AML-3D10 and dHL-60) cells 
following silencing of JAK3. (B) Fes activity of MCF10A and MDA-MB-231 cells following 
transfection of Fes or JAK3 plasmid DNA (the Fes plasmid was uses as a positive control for Fes 
kinase activity).  (C) JAK3 activity of MCF10A and MDA-MB-231 cells following transfection 
of Fes or JAK3 plasmid DNA (the JAK3 plasmid was uses as a positive control for JAK3 kinase 
activity).  Panel B indicates an effect of JAK3 on Fes more prevalent than the converse, Fes on  
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(Figure 13 legend continued) 
JAK3 (Panel C). The symbols * and # denote statistically significant (p<0.05) differences 
(increases or decreases, respectively) between samples and controls. Results in this figure are the 
means + SEM from at least 3 independent experiments conducted in duplicate. 
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F. JAK3, Fes and PLD2 regulate cell proliferation  
 Finally, I examined the biological significance of the roles of JAK3, Fes and PLD2 in the 
transformed cells and untransformed cells. First I transfected cell with DNA constructs and 2 
days after this, I performed cell proliferation assay. In Figure 14A, PLD2 accelerated cell 
proliferation in both transformed cells and untransformed cells. Fes overexpression has slight 
positive effect of cell proliferation while a highly significant one in MDA-MB-231 cells. Further, 
cell proliferation was slightly positively affected upon JAK3 overexpression in the 
untransformed cells while being highly accelerated in MDA-MB-231 cells. Although I saw that 
JAK3 inhibits PLD2, JAK3 here is able to stimulation cell growth since JAK3 has been 
implicated as a cell proliferation factor by interacting with other signaling molecules. 
 I also examined the change in cell proliferation when JAK3, Fes and PLD2 are silenced, 
individually or in combinations. As shown in Figure 14B, silencing PLD2 and Fes slowed cell 
growth in both cell lines while to the lesser extent in the untransformed cells. Depletion of JAK3 
slightly increased cell growth in the MCF10A cells but showed a significant inhibition of cell 
growth in the cancer cells. When the three proteins are transfected together, proliferation is 
decreased in both cell lines but such negative impact is greater in the MDA-MB-231 cancer cells. 
G. The existence of a new signaling pathway: JAK3 → Fes → PLD2 and mechanism of 
inter-regulation 
Figure 15 left presents the putative series of events that could be taking place in 
transformed cells, cells that have a heightened JAK3→Fes→PLD2 pathway with respect to 
untransformed cells. This new pathway affords the cell several regulatory points that are up-
regulated in the human breast cancer cell line MDA-MB-231. The reasons for elevated PLD2  
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Figure 14. The effect of PLD2, Fes or JAK3 overexpression or silencing on cell  
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(Figure 14 legend continued)  
proliferation in non-transformed versus transformed cells. (A) Cell proliferation of MCF10A 
or MDA-MB-231 cells in the presence of overexpressed PLD2, Fes or JAK3 60 hr post-
transfection.  (B) Cell proliferation of MCF10A cells at varying time points using Control 
siRNA, siJAK3, siFes+siPLD2 or siJAK3+siFes+siPLD2 (300 nM each). (C) Cell proliferation 
of MDA-MB-231 cells with similar conditions as Fig. 7A. Silencing all three proteins in 
transformed MDA-MB-231 cells (C) leads to a more significant decrease in cell proliferation 
when compared to the untransformed MCF10A cells (B).  Results in this figure are the means + 
SEM from at least 3 independent experiments conducted in duplicate. The symbols * and # 
denote statistically significant (p<0.05) differences (increases or decreases, respectively) 
between samples and controls. 
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Figure 15. Model for the new PLD2-Fes-Jak3 pathway.  In MCF10A cells, both the protein 
expression levels and the enzymatic activity of the three signaling molecules (PLD2, JAK and 
Fes) are maintained at a low level. A complex inter-regulation equilibrium composed of 
activations and inhibitions keep PLD and the synthesis of PA in balance and a basal level.  In 
MDA-MB-231 cells, the situation is very different; both the protein expression levels and the 
activity of PLD2, JAK and Fes are up-regulated. The kinases activate PLD that is then 
synthesizing higher amounts of PA. Further, this PA feeds back positively on Fes that upon 
binding to the phospholipid is further activated.   
56 
 
activity in cancer cells appear to be multiple and can be thought out as follows: (1) EGF-R 
activation leads to PLD2 up-regulation and to a quick and robust PA generation; (2) parallel to 
this event, Fes autophosphorylates and also phosphoryolates JAK3 which increases Fes activity; 
(3) PA generated by PLD2 upregulates Fes for its further activation and, in turn, Fes interact with 
PLD2 through the SH2 binding motif and stimulates it. (4) JAK3 activation contributes to higher 
PLD2 activity and it also interacts with other signaling molecules which lead to up-regulated 
abnormal cell proliferation in MDA-MB-231 cells.  
In MCF10A untransformed cells (Figure 15 left), Fes has inhibitory effect on JAK3 so 
that JAK3 activity is at basal level. Fes does not interact with PLD2 by its SH2 domain but at 
sites that remains to be discovered. Since substrate binding to the SH2 domain is necessary to 
optimal Fes activity, Fes activity is low in these cells. JAK3 keeps PLD2 activity low by 
interacting with PLD2 through the PLD2-Y415 residue, while Fes also competitively binds to 
PLD2. Due to the lower activities of these two tyrosine kinases JAK3 and Fes, PLD2 activity is 
kept in balance that is less abundant in untransformed MCF10A cells. 
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AIM 2: Serum deprivation confers on the MDA-MB-231 cell line a survival mechanism 
operating through a pathway involving EGFR/JAK3/PLD2. 
A. JAK3 is a major regulator of PLD2 and cell invasion 
In the previous aim I have studied PLD2 with respect to cell proliferation. In this part, I 
investigated a possible role of PLD2 in cell invasion. I measured both PLD enzymatic activity 
and cell invasion in Matrigel.  In Figure 16A and 16B I demonstrated that JAK3 was a critical 
regulator of PLD2 activity in both leukemic cell lines dHL-60 and 3D10 cells, extending our 
understanding of JAK3 regulation past the previously studied cell line. However, I discovered 
that JAK3 actually caused a decrease in PLD2 activity that was statistically significant in MDA-
MB-231 cells (p<0.05 by t-test).   
I silenced JAK3 in Figure 16C, and demonstrated the converse of what was shown in 
Figure 16A and 16B. Again, JAK3 appeared to have an inhibitory role in MDA-MB-231 cells in 
terms of lipase activity. Next I performed a Matrigel invasion analysis of MDA-MB-231 cells. 
Figure 16D demonstrates that invasion of cells was abrogated by JAK3 overexpression. 
Furthermore, invasion of cells was enhanced when silencing RNA targeting JAK3 was utilized. 
Taken together, these results suggest that PLD2 mediated cell invasion is inhibited by JAK3. It 
should be noted that these results (Figure 16) are the result of non-starved cells, wherein previous 
results (relevant to Aim 1) were done using serum starved cells. JAK3 seems to activate PLD2 
upon serum starvation. 
B. Serum deprivation induces JAK3 and PLD2 activity elevation 
It is known that cancer cells are sensitized to stress. Upon oncogenic transformation, a 
cell activates its stress mechanism for protective purposes. In order to survive, transformed cells  
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Figure 16. PLD2 is inhibited by JAK3 in exponentially growing MDA-MB-231 cells. (A) 
Analysis of endogenous PLD activity in exponentially growing cancer cells. Leukemic cell lines 
HL-60 and eosinophilic Eo-3D10 were maintained in suspension, whereas breast cancer MDA-
MB-231 were maintained in monolayer cultures. Cell lysates (~1 mg/ml protein concentration) 
were prepared and incubated with 1 µg of recombinant JAK3 (RecJAK3) for 20 min and then 
used for PLD activity measurement with PC8 in liposomes and [3H]-butanol as indicated in 
Material and Methods. (B) Analysis of transected PLD activity in exponentially growing cancer 
cells. Cells were transfected with myc-pcDNA3-PLD2-WT (2 µg DNA per condition) for two  
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(Figure 16 legend continued) 
days. After this, they were lysed and incubated with 1 µg of recombinant JAK3. (C) Effect of  
silencing JAK3 in cancer cells. Cells were transfected with either dsRNAs against JAK3 (si-
JAK3) or siControl, at 250 nM, for four days, after which PLD activity was assayed in vitro. (D) 
Analysis of cell invasion. After transfection with either DNA (PLD2 construct) or RNA 
(silencing), cells were resuspended in RPMI-based chemotaxis buffer and 1x104 cells were 
placed on the upper or "insert" chambers of 6.5-mm, 8-µm pore diameter, and modified 
Transwell inserts layered with “Matrigel”. To begin cell invasion, 3 nM EGF was added to the 
bottom wells. Results in this figure are the means + SEM from at least 3 independent 
experiments conducted in duplicate. The symbols * and # denote statistically significant (p<0.05) 
differences (increases or decreases, respectively) between samples and controls. 
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have to suppress stress signals that drive cells to senescence or move to locations with less 
stressful environment. In this part, I wanted to ascertain if stress conditions similar to those that a 
cancer cell might encounter (such as nutrient deprivation) could affect PLD activity. I speculated 
that the regulation of PLD2 regulation in MDA-MB-231 cells by JAK3 was due to differences in 
PLD2 expression and management of PLD2 activity by other effector molecules. It has 
previously been demonstrated that serum starvation is a factor which activates PLD2, which 
generates survival signals (148). In Figure 17A, I present data that indicates that JAK3 becomes 
a positive regulator of PLD2 mediated invasion after 16 hours. After two hours, JAK3 loses its 
inhibitory function against cell invasion.  
In addition to an increase in cell invasion upon starvation, I also noted increases in PLD2 
and JAK3 enzyme activities. In Figure 17B and 17C, graphs show the increase in PLD2 and 
JAK3 activities upon further starvation of cells. Apart from starvation, it appears that downward 
shifts in media pH also affect activation of the two proteins. Cells cultured in minimum nutrient 
media can be rescued by addition of 15% human serum.  
C. The small molecule inhibitor Apigenin allowed dissecting out the inter-regulation 
between JAK3 and PLD2 
To generate a better understanding of JAK3’s role in PLD2-mediated cell invasion in 
breast cancer cells, the flavonoids apigenin (4’,5,7-trihydroxyflavone) and Genistein and the 
quinazoline Janex-1 were used as inhibitors of JAK3. Figure 18A demonstrates that apigenin is 
the best inhibitor of JAK3 activity in vivo as compared to the other flavonoids used.   Apigenin 
induces >60% inhibition at a concentration of 30 nM and >80% at a concentration of 100 nM. 
Based on the promising results that were seen with apigenin’s inhibition of JAK3, I next  
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Figure 17. JAK3 stimulates cell invasion after cell starvation. (A) Effect of increasing 
concentrations of a JAK3 transfection construct on cell invasion of non-starved or 2-hr or 16-hr  
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(Figure 17 legend continued) 
starved MDA-MB-231 cancer cells. Two days after transfection with JAK3, cells were washed 
off the regular media and incubated for the for the indicated times in serum-free media.  (B) 
Effect of serum deprivation on JAK3 kinase activity of MDA-MB-231 cancer cells. Cells were 
cultured in regular media (Control), in serum-free media, in minimum media (OptiMEM), in 
pH=6.5 media or in serum-free media for 16 hr and 15% human serum added back for 1 hr. 
100% JAK3 activity represents 5,940 + 50 cpm/mg protein. (C) Effect of serum deprivation on 
PLD lipase activity of MDA-MB-231 cancer cells, under the same experimental conditions as in 
panel (B). 100% PLD activity represents 2,327 + 20 cpm/mg protein. Results in this figure are 
the means + SEM from 3 independent experiments conducted in duplicate. The symbols * and # 
denote statistically significant (p<0.05) differences (increases or decreases, respectively) 
between samples and controls. 
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Figure 18. The JAK3 tyrosine kinase inhibitor Apigenin inhibits cell invasion.  (A) Testing 
the potency of 3 tyrosine kinase inhibitors in JAK3 activity. Shown is the effect of increasing 
concentrations of apigenin, genistein and Janex-1 (each dissolved in 1 µl DMSO, final 
concentration) on MDA-MB-231 cells in vitro. Control cells received DMSO (1 ml/ml, final 
concentration) only. (B,C,D) Effect of increasing concentrations of apigenin on cell invasion in 
MDA-MB-231 (B), MTLn3 cancer cells (C), and H1299 cancer cells (D) in Matrigel using 3 nM 
EGF as chemoattractant for 16 hours. Control cells received no EGF (0 nM EGF). In the x-axis,  
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(Figure 18 legend continued) 
for zero apigenin in both 0 nM EGF or 3 nM EGF, cells were incubated with DMSO alone        
(1 µl/ml, final concentration). Results in each panel are the means + SEM from 3 independent 
experiments conducted in duplicate. 
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performed experiments to see if apigenin could abrogate cell invasion mediated by JAK3 in 
MDA-MB-231 cells and if these results could be extrapolated to other cancer cell lines. 
Figures 18B-D demonstrates that apigenin has a robust inhibitory effect in the three 
cancer cell lines. To further investigate this I returned to the subject of this study, MDA-MB-
231, and asked if cell invasion was inhibited depending on the time of exposure. Figure 19A,B 
indicates that apigenin (at 3 nM) inhibits responses to EGF at about nine hours. Thus, apigenin, 
at nanomolar concentrations, appears to be a powerful inhibitor of cancer cell invasion. 
D. JAK3 is upstream PLD2 in signaling and positively modulates it 
The next logical step was to examine whether apigenin had an effect on other tyrosine 
kinases other than JAK3. As cells were stimulated with EGF, I concentrated on the EGF receptor 
(EGFR). Figure 20A shows that apigenin robustly inhibits JAK3 but it also decreases EGFR 
activity, although at a lesser extent than it does JAK3. Dose-response curves indicate that 
apigenin inhibits the two kinases with IC50 of around 1 nanomolar for JAK3 and twenty 
nanomolar for EGFR, with maximal inhibitions of  ~80% and ~50%, respectively. Next, I 
measured PLD activity when cells were subjected to overexpression of tyrosine kinases EGFR 
and JAK3 constructs, and also the effect of both apigenin inhibition and JAK3 silencing (the 
latter as a more direct test of JAK3 than apigenin that can also inhibits EGFR, Figure 20A). 
Figure 20B and D demonstrate that: (a) JAK3 and EGFR overexpression enhances endogenous 
PLD2 activity within MDA-MB-231 cells; (b) PLD activity is at its highest when PLD2 is co-
transfected along with JAK3 or with EGFR, and negated by dsRNA silencing; and (c) apigenin 
does not inhibit PLD2 directly, but rather it negates the increasing effect it receives from JAK3  
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Figure 19. Apigenin inhibits both the rate and the extent of cell invasion. (A) Effect of cell 
migration in the presence of apigenin (open circles), EGF (filled squares), EGF with apigenin 
(open squares) and control (filled circles).MDA-MB-231 cells were pre-incubated with Apigenin 
and transferred to the insert of the Matrigel upper wells. Lower wells received, were appropriate, 
3 nM EGF as chemoattractant. (B) In selected samples, treated as indicated in (A), cells that had 
invaded the Matrigel layer and migrated to the underside of the filter were processed. Shown are 
representative hematoxylin-stained Matrigel images with increasing concentration of apigenin as 
a function of time, visualized in an optical microscope at x20. 
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Figure 20. JAK3 effect on PLD2 is reversed by apigenin and by silencing JAK3. Even 
though apigenin does not inhibit PLD activity directly, it acts upon JAK3 that itself regulates 
PLD2. (A) Effect of increasing concentrations of apigenin on EGFR or JAK3 tyrosine kinase 
activities measured in vitro. (B,C,D) Effect of overexpression (B) or silencing (C,D) of JAK3 on 
PLD2 activity in MDA-MB-231. Shown in (D) is a Western blot of cell lysates form MDA-MB-
231 silenced for 4 days with dsRNA against JAK3, with actin levels included, for protein loading 
controls. Results in this figure are the means + SEM from at least 3 independent experiments 
conducted in duplicate. The symbols * and # denote statistically significant (p<0.05) differences 
(increases or decreases, respectively) between samples and controls. 
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(but slightly less form EGFR). All this indicates that JAK3 is above PLD2 in a cell-signaling 
pathway with JAK3 modulating (positively) the phospholipase. As known, EGFR is a 
membrane-receptor tyrosine kinase that sits above JAK3, indicating that the system at hand is 
operating as an EGFR/JAK3/PLD2 pathway. 
E. Cell invasion is enhanced by PLD2 and JAK3 but abrogated by Apigenin and FIPI  
treatment 
In addition to tyrosine kinases, I examined serine/threonine kinases in evaluation 
inhibition through apigenin. I utilized S6K and mTOR plasmids that our laboratory possessed as 
two models of serine/threonine kinases. Figure 21A demonstrates that all four kinases alongside 
PLD2 are capable of enhancing cell invasion, with the following order: PLD2 > EGFR > JAK3 > 
S6K ~ mTOR. Despite apigenin’s lack of direct inhibition of PLD2, it still is capable of 
inhibiting cell migration through kinases. As expected, serine/threonine kinases like mTOR or 
S6K were not affected by apigenin and theses were taken as important negative controls. 
Interestingly,  mTOR and S6K have a repressing role on PLD2 gene expression as our lab has 
noted earlier (126) and an enhancement of mTOR/S6K due to PLD-derived PA has been 
indicated before (149). 
As indicated in Figure 16, culturing cells in serum free media results in an increase in 
PLD activity. Figure 21B shows that serum-deprived cells in culture have an up-regulated 
EGFR/JAK3/PLD2-PA system and are especially sensitive to a combination of JAK3 and PLD2 
enzymatic activity inhibitors (30 nM apigenin and 300 nM FIPI, respectively).  
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Figure 21.  An upregulation of cell invasion by PLD2 and JAK3 overexpression is 
abrogated by Apigenin and FIPI treatment. (A) Effectors of cell migration in the presence of 
30 nM apigenin during cell invasion assay or from cells that had been silenced with dsRNA for 4 
days prior to the invasion assay. In either case, cells were serum-deprived cells for 16 prior to 
cell invasion. (B) Effect of PLD activity inhibitor FIPI (300 nM), the JAK3 inhibitor apigenin 
(30 nM), or a combination of the two, on cell invasion. The day before the experiment, cells 
were divided into two equal sets, one was kept cultured in normal media with serum and the  
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(Figure 21 legend continued) 
other was changed to a serum free media for 16 hours prior to cell invasion. Results are the 
means + SEM from at least 3 independent experiments conducted in duplicate. The symbols * 
and # denote statistically significant (p<0.05) differences (increases or decreases, respectively) 
between samples and controls.  
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F. A EGFRJAK3PLD axis enhanced cancer cell invasion in cancer cells 
I so far described a dependency of cell invasion by two kinases (EGFR and JAK3) and a 
phospholipase (PLD2). This multiple level provides regulatory flexibility and maximizes the 
aggressively invasive power of MDA-MB-231 cells. This is especially important in the absence 
of growth factors in serum or “survival mode”, coincidental with metastasis of these cells from 
the primary tumor to new locations. A model of the EGFR/JAK3/PLD2 system described in this 
thesis is presented in Figure 22. 
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Figure 22. The JAK3-PLD2 system underlies the highly invasive phenotype of cancer cells. 
A model depicting the results of this study. JAK3 switches from mild inhibition to robust 
promotion of cell migration through PLD2 during cell starvation, together with EGFR for 
maximal cancer cell survival.  
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VII. CONCLUSIONS AND DISCUSSION 
(a) Relevant to specific aim 1 
I observed the presence of the tyrosine kinases Fes and JAK3 in MCF10A (as a model of 
an untransformed cell line) and MDA-MB-231 (as a model of transformed cells), regulate one 
another and they also regulate PLD enzymatic activity.  This inter-regulation is qualitatively and 
quantitatively different in the two cell lines investigated.  The overall picture that emerged from 
my experiments is that in untransformed cells, both the protein expression levels and the 
enzymatic activity of the three signaling molecules (PLD2, JAK and Fes) are maintained at a low 
level.  A complex inter-regulation equilibrium composed of activations and inhibitions keep PLD 
and the synthesis of PA in balance and a basal level.  The situation is very different in 
transformed cells; both the protein expression levels and the activity of PLD2, JAK and Fes are 
up-regulated.  The kinases activate PLD that is then synthesizing higher amounts of PA. Further, 
this PA feeds back positively on Fes that upon binding to the phospholipid, is further activated.  
Thus, I report the existence of a new signaling pathway involving PLD2, JAK3 and Fes that is 
heightened in transformed cells.  As I also observed that cell proliferation is dependent on these 
three molecules and their inter-regulation, I concluded that this new pathway could be very 
important to promote abnormally high cell proliferation in cancer cells. 
Several experiments were carried over to elucidate this new pathway.  They were divided 
between (a) the effect of kinases on the lipase, as the effect of JAK3 on PLD2 and Fes on PLD2 
and (b) the effect of the two kinases amongst themselves.  
I observed the presence of JAK3 and Fes in MCF10A and MDA-MB-231 cells, and 
identified residues through which they are interacting with PLD2 and one another. Fes interacts 
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with PLD2 through the Y415 residue in MCF10A cells, wherein it phosphorylates that residue 
and induces activation. In MDA-MB-231 cells, the SH2 domain becomes more important, and 
interaction between Fes and PLD2 ceases when this domain is disrupted. In MCF10A cells, this 
domain is inconsequential, and interaction can still occur, whereas the converse is true in MDA-
MB-231 cells with the Y415 mutant. In PLD2, the two tyrosine residues Y169 and Y179 in the 
N-terminal PX domain are situated within the YxN motif that is a canonical target recognized by 
proteins that possess SH2 domains. The SH2 domain binding increases PLD2 activity in cancer 
cells, and also contributes to heightened Fes activity, due to the fact that binding of the SH2 
domain stabilizes kinase activity of Fes (35) and creates a positive feedback loop which re-
stimulates PLD2. The binding of Fes to the SH2 binding domain of PLD2 may be due to hyper-
phosphorylation of PLD2 thanks to EGF-R overexpression in cancer cells. In my results, I 
demonstrated that SH2i Fes binds more in MCF10A than wild-type, which may be due to 
heightened exposure of whatever site binds Y415. Loss of Y415 can be compensated by the SH2 
binding in cancer cells. Future studies should examine the binding site of Fes to Y415 on PLD2, 
as it is not known at this time.  
Additionally, I demonstrated that silencing JAK3 has an effect on PLD2 activity; PLD2 
activity is increased in MCF10A cells upon silencing of JAK3 and decreased MDA-MB-231 
cells, again highlighting the difference in regulation between the two proteins.  PLD2 has been 
previously shown to be abundant in cancer cells that promote cell growth (59). Targeting PLD2 
enzyme lipase activity with selective inhibitors has also been shown to have tremendous effects 
on decreasing metastasis and invasion (60). I have indicated here that PLD2 is controlled through 
both the JAK3 and Fes tyrosine kinases. JAK3 acts differentially in cancer cells, where it acts a 
positive regulator through the SH2 domain. Fes likewise shows a more dramatic effect in 
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positive regulation of PLD2 in cancer cells than normal cells (MCF10A). Taken together these 
differential interactions indicate why PLD2 is up-regulated, and helps to explain why the 
cancerous phenotype of MDA-MB-231 cells exists. 
I additionally examined Fes with context to phosphatidic acid, using a PA sensor plasmid 
that fluoresced upon binding of PA. This allowed for the characterization of sub-cellular 
localization of PA. In MCF10A cells, PA is sequestered the nucleus, where it is present in tightly 
contained vesicle structures. Upon stimulation of cells with EGF, the PA is released and becomes 
cytosolic. In MDA-MB-231 cells, the PA is perinuclear, and is not present in the nucleus. PA is 
also more abundant in MDA-MB-231 cells, possibly due to PLD2 hyperactivity. Upon 
stimulation with EGF, PA in MDA-MB-231 cells becomes cytosolic, similar to what was 
observed in MCF10A cells. Next I utilized immunochemistry to examine sub-cellular 
localization of Fes with context to PA. I found that MCF10A has PA and Fes co-localize in 
similar fashion to PA, becoming cytosolic upon stimulation with EGF. There is a more 
pronounced co-localization in MDA-MB-231 cells, especially with stimulation of EGF. This 
suggests that the EGF pathway induced the two to co-localize within the cytosol where they may 
play some part in further interactions with JAK3 or PLD2. Overall it indicated that Fes co-
localizes with and potentially binds Fes. I next examined Fes and JAK3 activities with context to 
phospholipids. I examined PA alongside phosphphatidylinositol 2,4,5 bisphosphate and 
phosphatidylcholine as controls. PA showed the most marked increase in Fes activity, while no 
increase in JAK3 activity. PIP2 increased Fes activity, but not to the extent that PA did.  
Phospholipids seemed to have little to no effect on JAK3 activity. I then examined Fes 
activity with varying amounts of PA in both MCF10A and MDA-MB-231 cells. Again, I found a 
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differential regulation of PA interaction, with PA increasing activity optimally at about 100 nM 
in MDA-MB-231 cells. No change was seen in MCF10A cells. It is possible that this is due a 
change in the exposure FX domain, which is known to interact with PA. It is known that Fer, a 
familial isoform of Fes, interacts downstream of PLD mediated PA generation through the FX 
domain which leads to heightened activity (53). It is possible that PA supplementation is fruitless 
in MCF10A cells due to its metabolization by a number of proteins, but in MDA-MB-231 cells 
PA remains steadily high due to heightened PLD2 activity and expression. Thus, the 
supplementation is enough to give Fes the boost required to up-regulate its activity. This finding 
suggests that the interplay between PLD2 and Fes is robust and is much more important in 
cancer cells. 
My next objective was to identify interactions between JAK3 and Fes kinases 
themselves. I first silenced JAK3 in a number of cell lines and measured Fes kinase activity. In 
all transformed cell lines and MCF10A cells, increasing concentrations of siJAK3 decreased Fes 
activity, suggesting a positive regulatory role for JAK3 and Fes activity. I then overexpressed 
JAK3 in MCF10A and MDA-MB-231 cells, and found that Fes activity is heightened as a result 
in both cell lines.  Additionally I also found that Fes inhibited JAK3. It is possible that the two 
interact through SH2 domains that both possess, however I speculate that they only 
phosphorylate one another without extensive binding.  
Overall, I developed a model which has Fes, JAK3, and PLD2 with Fes down-regulating 
JAK3 and JAK3 down-regulating PLD2 in normal, untransformed cells. Fes interacts with PLD2 
through the Y415 residue, which leads to stabilization of its activity. JAK3 down-regulates 
PLD2 through its kinase activity, and possibly through interaction through its SH2-L domain. 
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JAK3 may bind Y415 as well, which may be a site of inhibition. Fes may compete with JAK3 at 
this site, which provides stabilization by preventing inhibition by JAK3. Fes and JAK3 interact 
to down-regulate one another. In cancer cells the enhanced binding of Fes to PLD2 through its 
SH2 domain provides positive regulation as opposed to stabilization. This leads to an increase in 
PLD2 activity through Fes. Additionally, the PA generated by PLD2 in great abundance causes 
Fes to be stimulated, which feeds into a positive loop with PLD2. Furthermore, JAK3 acts 
positively on Fes in cancer cells, and Fes acts positively on JAK3. Due to the fact that the 
pathway is delicately regulated by competition between Fes and JAK3 in normal cells, the 
disruption of binding to PLD2 greatly disturbs the pathway generating a positive feedback loop, 
which leads to cytoskeletal reorganization and enhanced proliferation, contributing to the 
transformed phenotype.  
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CONCLUSIONS AND DISCUSSION (continued) 
(b) Relevant to specific aim 2 
Our laboratory has previously demonstrated that JAK3 is critical to cell chemotaxis in 
neutrophils (48). I initially observed that MDA-MB-231 cells did not rely on JAK3 for PLD2 
mediated proliferation and cell invasion. However, upon serum starvation of the cells JAK3 
became a positive signal in PLD2 activation and cell proliferation. Serum or nutrient (amino 
acids and glucose) removal also led to an increase in JAK3 activity that was reversed when those 
nutrients were added back to the serum. These experiments underscored the importance of JAK3 
and PLD2 during times of nutrient deprivation, wherein survival signals are generated through 
the JAK3 PLD2 signaling axis. 
An additional piece of evidence for the JAK3/PLD2 connection is given in this study by 
the use of the small molecule flavonoid inhibitor, apigenin. Apigenin does not directly inhibit 
PLD2, but rather inhibits JAK3 (that regulates PLD2). The decrease in PLD2 activity upon 
treatment with apigenin led us to believe JAK3 should be acting upstream of PLD2. I reasoned 
that apigenin’s inhibition of PLD2 is because JAK3 is unable to phosphorylate PLD2 in the 
presence of apigenin. There are other kinases indirectly participating in PLD2 activation, namely 
EGFR by means of JAK3 activation.  
Apigenin is a powerful (IC50=7-26 nM) inhibitor of invasiveness of cancer cells. In our 
hands, apigenin produces robust cell invasion inhibition at nanomolar concentrations, which is 
approximately 1000-fold less than the micromolar concentrations of apigenin (5-200 µM) used 
by others (1, 68). That apigenin would target JAK3 as a tyrosine kinase inhibitor is 
understandable in light of the work of Sudbeck et al., who has documented structural and 
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chemical features that facilitate binding of certain small inhibitor compounds to leukemic JAK3, 
which share a high level of similarity with apigenin (123). 
I depict a model of apigenin’s disruption of the PLD2-JAK3 signaling axis in Fig. 22. 
The model highlights how JAK3 switches from inhibiting to promoting PLD2 activity during 
cell starvation for cancer cell survival and works together with EGFR for maximal cell 
migration, and this effect is interfered with by apigenin.  
 In breast cancer cells, PLD activity is increased during starvation, and Dr. Foster’s group 
has labeled PLD as a "survival signal" (148). An elevated PLD could prompt cells to migrate, 
presumably outside the inner part of a solid tumor (115), and it could serve a “nutrient sensor” in 
cooperation with mTOR (149). According to the results presented here, starvation that involves 
the effective removal of growth factors, lipids and other components from serum in it elevates 
PLD activity but precisely through JAK3. Thus, JAK3 is a key modulator of PLD-mediated cell 
invasion. In these highly invasive cancer cells, when starved, the elevated PLD activity will 
provide intracellular PA and still be able to activate mTOR/S6K leading to the activation of the 
translation machinery in conditions in which normal cells would typically be apoptotic or dead. 
The results presented here provide evidence of a novel EGFR/JAK3/PLD2 system that is 
activated under cell survival mode. This allows enhanced cell migration and invasion, via PLD2, 
which are reversed by apigenin. This study also highlights the usefulness of apigenin as a 
powerful inhibitor of cancer cell invasion. 
In summary, this second part of the thesis elucidated a multi-layered activation of cell 
invasion by two kinases (EGFR and JAK3) and a phospholipase (PLD2) provides regulatory 
flexibility and maximizes the aggressively invasive power of MDA-MB-231 breast cancer cells. 
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This is especially important in the absence of growth factors in serum, coincidental with 
migration of these cells to new locations. 
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VIII. SIGNIFICANCE OF THIS STUDY 
This project shows here a novel signaling pathway involving JAK3, FES and PLD2 in 
vivo, which participates in cell proliferation. This pathway was tested in a number of normal, 
untransformed cells (breast epithelial MC10A and COS-7 fibroblasts) and transformed, highly 
proliferative cells (MDA-MB-231 and MCF7 breast cancer cells, AML3D10 and HL60 
myeloblasts).  The experimental results here demonstrate the highly regulated control that JAK3, 
Fes and PLD2 exert on some aspects of intercellular signaling in cancer. Additionally, we 
present evidence that JAK3 and PLD2 communicate with one another through a pathway that is 
activated upon starvation of cells. This pathway accentuates invasiveness of cells during times of 
stress and also results in an increase of cell invasion. The pathway can be quelled by addition of 
the flavonoid apigenin, which inhibits JAK3 as well as EGFR (which activates JAK3). Both of 
these events down-regulate PLD2 activity and cell invasion. The results presented in this thesis 
demonstrate an overall pathway in which Fes, JAK3 and PLD2 participate to up-regulate 
proliferation of cells and enhance the invasiveness of breast cancer cells. These novel 
mechanisms of PLD2 signaling present potential therapeutic targets to prevent cancer 
progression.    
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